EVOGENE LTD. (EVGN) — Analysis Summary
EVOGENE LTD. (EVGN) has a market cap of $5.62M with year-over-year revenue growth of -54.7%. Net margin stands at -203.1%. The stock trades at a P/E ratio of -0.7.
Key Takeaways
- Revenue changed -54.7% year-over-year
- Net margin of -203.1%
- P/E ratio of -0.7
Compared with its sector, EVGN posted revenue growth of -54.7% and trades at a P/E of -0.7.
EVOGENE LTD. (EVGN)
UPDATED — ET · SOURCE POLYGON
Red Flags & WarningsHigh Risk Signals
Multiple material red flags are active and deserve closer underwriting before relying on any valuation output.
Interest coverage at -7.3x — earnings do not cover interest payments
Operating margin at -364.2% — severe operating losses
Net margin at -203.1% — losses exceed revenue (possible one-time charges)
Negative gross margin (-6.3%) — selling below cost
Evogene Ltd is a computational biology company targeting to revolutionize product development for life-science based industries, including human health, agriculture, and industrial applications. The company established its technology, the Computational Predictive Biology (CPB) platform. The CPB platform is designed to computationally discover and develop life-science products based on microbes, small molecules, and genetic elements as the core components for such products. It holds several subsidiaries utilizing the CPB platform for the development of human microbiome-based therapeutics, medical cannabis, ag-biologicals, ag-chemicals, seed traits, and ag-solutions for castor oil production. It generates maximum revenue from the industrial segment, followed by Agriculture.
Employees
52
Exchange
XNAS
Systematic competitive advantage assessment based on 4yr data
This assessment is based on quantitative analysis of historical financial data and does not constitute investment advice. Moat ratings may change with industry and competitive dynamics.
First version surfaces recent SEC Forms 3, 4, and 5 activity. It does not yet parse individual buy/sell transactions.
Capital Structure
Cash Flow
Disclaimer: This is not financial advice. Data sourced from SEC EDGAR and Polygon.io. Past performance does not guarantee future results. Always conduct your own research before making investment decisions.